Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion upfront
- Johnson & Johnson agreed to acquire eye-disease drug developer Ollin Biosciences for $2.2 billion upfront.
- Regulatory and commercial milestones could reach approximately $1.13 billion; closing is expected before the end of 2026.
- The acquisition would add OLN324, an investigational bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema, to its pipeline.
- Blackstone Life Sciences will provide $750 million over multiple years to fully fund OLN324’s Phase 3 development, contingent on acquisition closing.
- In return, Blackstone will be eligible for regulatory and sales milestone payments, as well as single-digit royalties.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20261116907414) on November 16, 2026, and is solely responsible for the information contained therein.